试验终止ClinicalTrials.gov(美国登记平台)来源日期:2024-11-22
A Study of TAK-951 in Healthy Adults
编号:NCT06610279登记状态:提前终止企业 / 申办者:Takeda
药物 / 成分:TAK-951、Placebo
登记的停止原因(原文):The study was terminated based on the Sponsor's decision attributed to the benefit-risk profile derived from the Part 1 data of this study.
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2024-11-21
Highly Active Antiretroviral Therapy for Patients With Primary Biliary Cirrhosis
编号:NCT01614405登记状态:提前终止企业 / 申办者:University of Alberta
药物 / 成分:TDF/FTC/LPV/r、Placebo
登记的停止原因(原文):Protracted gastrointestinal symptoms were experienced by most patients who were subsequently found to be in the treatment arm on LPV/r. This observation resulted in cessation of enrolment and a decision not to continue the RCT
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2024-11-21
Study of MK-8353 in Combination With Pembrolizumab (MK-3475) in Participants With Advanced Malignancies (MK-8353-013)
编号:NCT02972034登记状态:提前终止企业 / 申办者:Merck Sharp & Dohme LLC
药物 / 成分:MK-8353、Pembrolizumab
登记的停止原因(原文):business reasons.
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2024-11-21
Idelalisib+Obinutuzumab in Patients With Relapsed/Refractory Follicular Lymphoma
编号:NCT03890289登记状态:提前终止企业 / 申办者:Fondazione Italiana Linfomi - ETS
药物 / 成分:Idelalisib、Obinutuzumab
登记的停止原因(原文):Study was halted prematurely due to safety, since tocity stopping rules have been met
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2024-11-21
Polydiuretic Therapy for HFpEF, a Randomised Controlled Trial
编号:NCT05129722登记状态:提前终止企业 / 申办者:The George Institute
药物 / 成分:Low dose combination polydiuretic therapy、Comparator monotherapy empagliflozin
登记的停止原因(原文):Difficulties in recruitment at both sites.
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2024-11-21
A Study to Explore the Efficacy of Alprostadil Liposomes Injection in the Prevention of CI-AKI
编号:NCT05475717登记状态:提前终止企业 / 申办者:CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
药物 / 成分:Alprostadil liposome injection
登记的停止原因(原文):Voluntarily suspended the trial due to strategic adjustments
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2024-11-21
TT-816 As Monotherapy or in Combination with a PD-1 Inhibitor in Patients with Advanced Cancers (SEABEAM) (MK3475-E88)
编号:NCT05525455登记状态:提前终止企业 / 申办者:Teon Therapeutics, Inc.
药物 / 成分:TT-816、A PD-1 inhibitor
登记的停止原因(原文):Company operational decision. Decision to stop study is not due to safety or efficacy concerns.
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2024-11-21
ME-344 and Bevacizumab in Previously Treated Metastatic Colorectal Cancer
编号:NCT05824559登记状态:提前终止企业 / 申办者:MEI Pharma, Inc.
药物 / 成分:ME-344、Bevacizumab
登记的停止原因(原文):Company decision to wind down operations, close all clinical programs and evaluate strategic options
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2024-11-21
Treatment of Elevated Blood Pressures in Early Pregnancy
编号:NCT05955040登记状态:提前终止企业 / 申办者:Marshall University
药物 / 成分:Nifedipine、Labetalol
登记的停止原因(原文):The study has closed due to difficulty in enrollment.
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2024-11-20
A Phase I Study of Quadrivalent Human Papilloma Virus (HPV) (Types 6, 11, 16, 18) Recombinant Vaccine in HIV-Infected and HIV-Negative Pre-Adolescents, Adolescents, and Young Adults
编号:NCT00798265登记状态:提前终止企业 / 申办者:National Cancer Institute (NCI)
药物 / 成分:Gardasil、Survey
登记的停止原因(原文):Study closed due to low accrual.
查看官方原始记录 ↗